Stevens C

Biography

Stevens C, MD, has more than 17 years of biopharmaceutical drug development experience, including strategy, execution, and operations management for US and European clinical trials and regulatory filings, through senior management positions as a medical lead and as a leading industry consultant. Prior to joining Arsanis, Dr. Stevens spent more than a decade consulting for nearly 30 companies assisting with all stages of drug development in the US and Europe. While working with Cubist Pharmaceuticals, he guided the development strategy for surotomycin for the treatment of C. difficile infection from IND filing to the completion of its successful Phase 2 trial. As a strategic consultant for Dyax, he supported the development of peptide and monoclonal antibody therapies for hereditary angioedema. He also served on the Millenium/Takeda team that led to the approval of vedolizumab for both the Crohn’s disease and ulcerative colitis treatment indications in the US and Europe. He served as Senior Vice President of Clinical Development at Alnara Pharmaceuticals and also previously held medical director roles at Circe Biomedical and Altus Pharmaceuticals. Dr. Stevens spent 10 years as a clinical and research gastroenterologist at Beth Israel Deaconess Medical Center in Boston and as an assistant professor of medicine at Harvard Medical School, during which he authored more than 30 peer-reviewed publications. He holds a Bachelor of Arts in Chemistry from the University of North Carolina at Chapel Hill and earned his Medical Degree from the University of Miami.

Research Interest

Immunology